


PATENT
Customer Number 22,852
Attorney Docket No. 6483.0009-08

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Keith E. Langley et al.) Group Art Unit: 1645
Serial No.: 08/803,954) Examiner: R. Hayes
Filed: April 20, 2000)
For: METALLOPROTEINASE)
INHIBITOR)



RECEIVED

MAR 22 2001

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

DECLARATION OF YVES A. DE CLERCK

I, Yves A. De Clerck, do hereby make the following declaration:

1. I am a co-inventor of U.S. Application Serial No. 08/803,954 ("the '954 application"), which claims priority based on U.S. Application No. 07/355,027 filed May 19, 1989. I am employed by Childrens Hospital Los Angeles., which is an assignee of the '954 application. My position is Vice-President of Research and Professor of Pediatrics, Biochemistry and Molecular Biology.
2. In 1988 and 1989, I worked for Childrens Hospital Los Angeles.
3. Example 5 of the '954 application describes a method for purifying recombinant human TIMP-2 from *Escherichia coli* and states: "A sample of the human MI [TIMP-2] preparation described (about 6.5 g) was subjected to amino-terminal amino acid sequencing through 18 cycles, using the method described in Example 2."

4. The work on expressing recombinant human TIMP-2 in *E. coli* and on purifying that protein from *E. coli* was performed at Amgen Inc, not in my laboratory at Childrens Hospital Los Angeles.


5. I had no knowledge at the time and I do not know now what sample of recombinant human TIMP-2 was submitted for N-terminal amino acid sequencing or how that sample was purified.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Dated: [Date]

1/24/11

By:


Yves A. De Clerck